Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.06% Nasdaq Down0.01%

Prana Biotechnology Limited (PRAN)

-NasdaqCM

2.39 Up 0.10(4.37%) May 24, 3:59PM EDT

Add to Portfolio
ProfileGet Profile for:
Prana Biotechnology Limited
369 Royal Parade
Level 2
Parkville, VIC 3052
Australia - Map
Phone: 61 3 9349 4906
Fax: 61 3 9348 0377
Website: http://www.pranabio.com

Details 
Index Membership:N/A
Sector:N/A
Industry:N/A
Full Time Employees:8

Business Summary 

Prana Biotechnology Limited engages in the research and development of therapeutic drugs for the treatment of neurological disorders in Australia. The company primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer, age-related macular degeneration and cataract, Motor Neuron, and Creutzfeldt-Jakob diseases. Its development stage product line comprises PBT2, a Phase IIb clinical trial product for the treatment of Alzheimer’s disease; and PBT2, a Phase IIa clinical trial product for the treatment of Huntington’s disease. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Prana Biotechnology Limited
Key Executives 
 PayExercised
Mr. Geoffrey Paul Kempler B.Sc, Grad.Dip.App.Soc.Psych, 58
Co-Founder, Exec. Chairman and Chief Exec. Officer		426.00KN/A
Mr. Richard Revelins B.Ec., 51
Chief Financial Officer and Company Sec.		83.00KN/A
Ms. Dianne Angus , 53
Chief Operating Officer		352.00KN/A
Prof. Dr. Rudolph Emile Tanzi Ph.D.,
Chief Scientific Advisor and Member of R&D Advisory Board		N/AN/A
Dr. Craig W. Ritchie M.D.,
Chief European Clinical Advisor and Member of R&D Advisory Board		N/AN/A
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.